Novo Nordisk’s Pinder Sahota appointed President of the ABPI

Pinder Sahota, General Manager and Corporate Vice President of Novo Nordisk UK has been confirmed as the new President of the Association of the British Pharmaceutical Industry (ABPI) from today (Friday 29 April).

After decades of scientific investment, we are now seeing the next generation of cutting-edge treatments being made available to patients. I’m determined to use my term as President of the ABPI to make sure that new, innovative medicines reach the people who need them. Pinder Sahota, President of the ABPI

Pinder also Chairs the CBI’s Health Council and has previously served as Vice Chair of the European Medicines Group.

Pinder will lead on overseeing the ABPI, the ABPI Board, and the ABPI’s Code of Practice, which is administered by the Prescription Medicines Code of Practice Authority (PMCPA). He takes over from outgoing President, Ben Osborn of Pfizer.

Pinder takes up the Presidency at a critical time for industry, and one year on from the publication of the Government’s Life Sciences Vision. Ensuring the Vision becomes a reality for UK patients and the life sciences sector will be integral to Pinder’s Presidency. Central to this is working with Government to ensure the NHS is supported, and patients are receiving the innovative medicines they need.

Pinder Sahota, President of the ABPI, said:

“After decades of scientific investment, we are now seeing the next generation of cutting-edge treatments being made available to patients. I’m determined to use my term as President of the ABPI to make sure that new, innovative medicines reach the people who need them.

The past two years have demonstrated just how important medicines and vaccines are to our way of life. Improving how we use new medicines can now support the NHS to recover from the pandemic by addressing the significant variations which currently exist in care across the country.

There is a real opportunity for the UK to build on our scientific excellence and continue to help patients across the country. I look forward to working closely with the Government, NHS and colleagues across the sector to make this a reality.”

Welcoming Pinder to the role, Richard Torbett, Chief Executive of the ABPI, said:

“I’ve hugely enjoyed working with Pinder during his time as Vice President of the ABPI, and give him a warm welcome to the Presidency from the whole ABPI.

Pinder is a passionate advocate for the industry and brings a wealth of experience to the Presidency.

I look forward to working with Pinder to deliver on the ABPI’s long term strategy to achieve our ambitions for the sector in the UK.”

Follow Pinder on LinkedIn here.

TAGS
  • Commercial

The ABPI exists to make the UK the best place in the world to research, develop and use new medicines. We represent companies of all sizes who invest in discovering the medicines of the future. 

Our members supply cutting edge treatments that improve and save the lives of millions of people. We work in partnership with Government and the NHS so patients can get new treatments faster and the NHS can plan how much it spends on medicines. Every day, we partner with organisations in the life sciences community and beyond to transform lives across the UK.